Genmab — April 2020
-
sgen negative estimeret eps på USD -0,99. market cap 21B USD. de må have andet end TV i pipeline for fremtidig indtjening....
-
amivantamab in phase II according this JNJ slide https://twitter.com/semodough/status/1250827516161527810/photo/1
-
I think it has been phase2 since dec 2018 ? At least according to other sources. There is a part 2 to the study https://clinicaltrials.gov/ct2/show/NCT02609776 Originally it was n=180 ?
-
God morgen
-
Genmab A/S (NASDAQ:GMAB) - SunTrust Banks boosted their FY2020 EPS estimates for shares of Genmab A/S in a research note issued to investors on Tuesday, April 14th. SunTrust Banks analyst A. Goonewardene now forecasts that the company will earn $0.24 per share for the year, up from their previous estimate of $0.23. SunTrust Banks has a "Buy" rating on the stock. SunTrust Banks also issued estimates for Genmab A/S's FY2022 earnings at $0.80 EPS and FY2023 earnings at $1.01 EPS.
-
GMAB has been the topic of a number of other research reports. Zacks Investment Research raised shares of Genmab A/S from a "sell" rating to a "hold" rating in a research report on Thursday, February 27th. HC Wainwright reduced their price target on Genmab A/S from $29.00 to $28.00 and set a "buy" rating for the company in a research report on Wednesday. Royal Bank of Canada reiterated a "buy" rating and issued a $27.00 target price on shares of Genmab A/S in a report on Monday, April 6th. Final
-
Finally, Morgan Stanley lowered their price objective on Genmab A/S from $31.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has an average rating of "Buy" and a consensus target price of $27.00.
-
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG boosted its holdings in shares of Genmab A/S by 11.5% in the 4th quarter. UBS Group AG now owns 5,190 shares of the company's stock valued at $116,000 after acquiring an additional 537 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Genmab A/S by 8.0% during the fourth quarter.
-
PNC Financial Services Group Inc. now owns 10,932 shares of the company's stock worth $245,000 after purchasing an additional 810 shares in the last quarter. Comerica Bank increased its stake in Genmab A/S by 2.5% in the fourth quarter. Comerica Bank now owns 38,449 shares of the company's stock valued at $893,000 after purchasing an additional 944 shares during the last quarter.
-
Kayne Anderson Rudnick Investment Management LLC increased its stake in Genmab A/S by 0.9% in the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 127,189 shares of the company's stock valued at $2,840,000 after purchasing an additional 1,170 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of Genmab A/S by 28.6% in the fourth quarter.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind